Global Epilepsy Therapeutics Market To Reach $18.1 Billion By 2028

09-Jun-2022 | Zion Market Research

The global epilepsy therapeutics market was valued at over $13 billion in 2021 and is likely to surpass $18.1 billion by the end of 2028. The market is expected to expand at a considerable CAGR of 3.5% during the forecast period.

Epilepsy implies chronic neurological disorder that can result in unfounded and continuous seizures. A person suffering from this disease can be subject to seizures with no clarification. Previous brain injury or any traumatic event can result in these seizures; however, the actual reasons are still unidentified. Usually, this condition is found among adults and children; though elderly people are at more risk of getting the condition. Epilepsy medications or therapeutics are the preliminary treatment option for almost every patient with multiple seizures. The medications avert seizures by reducing the propensity of the brain cells to direct disorganized and excessive electrical impulses.

The global epilepsy market is projected to witness substantial expansion during the forecast period. This can be attributed to factors such as the rising incidence of epilepsy cases globally along with growing attentiveness towards the treatment of the same market. Further, the growing elderly population, increasing R&D in both developing & developed markets, and implementation of anti-epileptics owing to rising epilepsy & seizures cases are other factors driving the global market growth. In addition, manufacturers have come up with several novel therapeutics that assist in treating epilepsy effectively owing to elevated R&D and investment activities. Nonetheless, factors like lack of cognizance regarding the condition and disinclination to accept epilepsy medications will hamper the expansion of the global market to some extent.

The global epilepsy therapeutics market can be segmented into distribution channels, drugs, and region. By distribution channel, the market can be segmented into pharmacy stores, hospitals, pharmacies, and others. By drugs, the market can be segmented into first generation, second generation, and third-generation antiepileptics. The second-generation epilepsy therapeutics segment is anticipated to grab a noteworthy market share due to its elevated infiltration in the market. Also, they are more effective in comparison to first-generation epilepsy therapeutics. Further, the third-generation epilepsy therapeutics segment is also likely to witness considerable market share as they are deemed to be very efficient with relatively few side effects.

Global Epilepsy Market

The global epilepsy therapeutics market was governed by North America and is anticipated to maintain its top position during the coming period with the highest share. This growth can be attributed to the existence of cutting-edge healthcare infrastructure and fast-rising cases of epilepsy. Epilepsy is the fourth most common disorder in the US, as per the Epilepsy Foundation of Michigan. Additionally, around 1% of Americans suffer from some form of epilepsy disorder. Furthermore, companies are launching aggressive campaigns to create awareness among people regarding epilepsy disorder and its successful treatment, which will also positively influence the growth of the regional market. Asia Pacific is projected to witness substantial growth during the forecast period due to factors such as the rapidly flourishing healthcare sector along with the rising disposable income of people.

Some of the significant players in the global epilepsy therapeutics market include Amneal Pharmaceuticals LLC, Upsher-Smith Laboratories, LLC., Eisai Co., Sunovion Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc., Novartis AG, Bausch Health Companies Inc., UCB S.A., and Pfizer, Inc.

Recent Developments:

  • Dr Reddy Laboratories Limited in July 2018 revealed the co-promotion and distribution agreement with USB S.A. for Briviact India. Briviact act was started for introducing successful treatment against the partial-onset seizure in patients aged above 16 years.
  •  Eisai Co. Limited in January 2020 introduced FYCOMPA in China. It was launched for treating partial-onset seizure in patients above the age of 12 years.

Browse the full Epilepsy Therapeutics Market By Drugs (First Generation Anti-Epileptics, Second Generation Anti-Epileptics, Third Generation Anti-Epileptics), By Distribution Channel (Hospital Pharmacy, Pharmacy Stores, Others), By Location (Rural And Urban), And By Region – Global And Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data And Forecasts 2022 – 2028.” Report at https://www.zionmarketresearch.com/report/epilepsy-therapeutics-market

Global Epilepsy Therapeutics market is segmented as follows:

By Types Covered

  • Anti-Epileptic Drugs
  • Brain Surgery
  • Dietary Supplements
  • Ketogenic Diet
  • Surgical Therapies

By End Users Covered:

  • Ambulatory Surgical Centers
  • Hospitals& Clinics
  • Home Care Settings
  • Neurology Centers

By Products Covered:

  • First Generation Epilepsy Therapeutics
  • Second Generation Epilepsy Therapeutics
  •  Third Generation Epilepsy Therapeutics

By Distribution Channels Covered:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy-User

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

About Us:
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:
Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com

Office Address

Contact Us

Zion Market Research
Tel: +1 (844) 845-5245
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #

US OFFICE NO +1 (844) 845-5245
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Industry Press Release

We Accept

We have secured system to process your transaction.

  • paypal
  • amazon
  • visa
  • master card

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed